
1. gastroenterol hepatol (n y). 2016 nov;12(11):679-689.

evolving new strategies medical management chronic hepatitis b virus
infection.

block tm(1), zhou t(1), anbarasan n(1), gish r(1).

author information: 
(1)dr block dr zhou professors project leaders baruch s.
blumberg institute doylestown, pennsylvania. mr anbarasan affiliated 
the baruch s. blumberg institute time article a
third-year medical student affiliated flushing hospital medical center
in flushing, new york. dr gish professor consultant department of
medicine division gastroenterology hepatology stanford
university stanford, california; principal robert g. gish consultants, llc,
in san diego, california; senior medical director st joseph's hospital and
medical center phoenix, arizona; chief medical advisor hepatitis b 
foundation doylestown, pennsylvania.

is cure chronic hepatitis b virus (hbv) infection possible? hepatitis c
virus infection routinely cured medically. growing expectation 
that new drugs management chronic hbv infection provide
substantial benefit current chronic hbv medications, if
not curative. although definition medically induced cure chronic
hbv infection varies, include sustained off-drug absence viremia and
negativity virologic markers. currently 29 drugs in
the pipeline tested management chronic hbv infection. this
article discusses potential drugs respect possible
contributions achieving medically induced cure.


pmcid: pmc5193088
pmid: 28035197 

